Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
Fiche publication
Date publication
juin 2023
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry, Dr DESMOULINS Isabelle, Dr JOUANNAUD Christelle
Tous les auteurs :
Grinda T, Antoine A, Jacot W, Cottu PH, de la Motte Rouge T, Frenel JS, Mailliez A, Dalenc F, Goncalves A, Clatot F, Mouret Reynier MA, Levy C, Ferrero JM, Desmoulins I, Uwer L, Petit T, Jouannaud C, Arnedos M, Chevrot M, Courtinard C, Tredan O, Brain E, Pérol D, Pistilli B, Delaloge S
Lien Pubmed
Résumé
Early metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation requiring urgent characterisation and handling. Epidemio-Strategy-Medico-Economical-Metastatic Breast Cancer (ESME-MBC) database, a multicenter, national, observational cohort (NCT03275311) provides recent data on this entity.
Mots clés
Breast cancer, ESME cohort, Overall survival, Real-world data, Triple-negative breast cancer
Référence
Eur J Cancer. 2023 06 7;189:112935